Benefit of treatment of latent tuberculosis infection in individual patients. Issue 5 (May 2016)

• Record Type: Journal Article
• Authors: Dobler, Claudia C.; Martin, Andrew; Marks, Guy B.
• Is Part Of: European respiratory journal. Volume 47:Issue 5(2016)
• Page Start: 1594
• Page End: 1595
• Publication Date: 2016-05
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.00175-2016
• Languages: English
• ISSNs: 0903-1936

Abstract

We read with interest the correspondence by K. Fluegge, which discusses inclusion of additional information in our recently published decision aid for treatment of latent tuberculosis infection (LTBI) [1]. K. Fluegge suggests that the dynamic robustness of the decision aid could be strengthened by including information on 1) treatment adherence, 2) transitional alternative treatment regimens ( e.g. transition from isoniazid to rifampicin after adverse events) and 3) ethnicity (as an indicator of tolerability to isoniazid based on genetics of isoniazid metabolism). High model complexity of a decision analysis for preventive tuberculosis treatment may result in overfitting http://ow.ly/Y8erf